首页> 美国卫生研究院文献>Frontiers in Oncology >Combination of Systemic Inflammation Response Index and Platelet-to-Lymphocyte Ratio as a Novel Prognostic Marker of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy
【2h】

Combination of Systemic Inflammation Response Index and Platelet-to-Lymphocyte Ratio as a Novel Prognostic Marker of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy

机译:全身炎症反应指数和血小板与淋巴细胞比率的组合作为根治性肾切除术后上路尿道上皮癌的新预后指标

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This study aimed to evaluate the preoperative prognostic value of systemic inflammation response index and platelet-to-lymphocyte ratio (SIRI-PLR) in patients with upper tract urothelial carcinoma (UTUC). The prognostic ability of SIRI-PLR was evaluated in a training cohort comprising 259 patients with UTUC who underwent radical nephroureterectomy and was further validated in an independent cohort comprising of 274 patients. Multivariate Cox regression models showed that SIRI was significantly associated with overall-survival (OS), cancer-specific survival (CSS), and metastatic-free survival (MFS), and PLR significantly affected OS and CSS (all P < 0.05). In particular, a simultaneously high SIRI-PLR value was considered an independent risk factor even after adjusting for confounding factors and was superior to SIRI alone in predicting survival among patients with UTUC. The analyses of concordance-index and receiver operating characteristic curve showed that incorporation of SIRI-PLR vs. without its incorporation into newly developed nomograms or currently available clinical parameters, such as pathologic T stage, N stage, or tumor grade, had higher accuracy in predicting urologic outcomes of patients with UTUC. These results were observed in the training cohort and were confirmed in the validation cohort. In conclusion, patients with a simultaneously high SIRI-PLR value had significantly poor prognosis. Incorporating SIRI-PLR into currently available clinical parameters can help in patient management.
机译:本研究旨在评估上尿路尿路上皮癌(UTUC)患者全身炎症反应指数和血小板与淋巴细胞比率(SIRI-PLR)的预后价值。 SIRI-PLR的预后能力是在259名接受根治性肾切除术的UTUC患者的训练队列中评估的,并在包括274名患者的独立队列中进一步进行了验证。多变量Cox回归模型显示SIRI与总生存期(OS),癌症特异性生存期(CSS)和无转移生存期(MFS)显着相关,而PLR显着影响OS和CSS(所有P <0.05)。特别是,即使在调整混杂因素之后,同时具有较高SIRI-PLR值也被认为是独立的危险因素,在预测UTUC患者的生存率方面优于单独SIRI。对一致性指数和接受者操作特征曲线的分析表明,将SIRI-PLR与未将其纳入新开发的列线图或当前可用的临床参数(例如病理T分期,N分期或肿瘤等级)相比,其准确性更高。预测UTUC患者的泌尿外科结果。这些结果在培训队列中观察到,并在验证队列中得到确认。总之,同时具有较高SIRI-PLR值的患者预后很差。将SIRI-PLR纳入当前可用的临床参数可以帮助患者管理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号